Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
A Randomized, Double-Blind, Placebo Controlled Trial of Simvastatin to Treat Alzheimer Disease
Neurol 77:556-563, Sano, M.,et al, 2011
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
A Randomized Placebo-Controlled Trial of Ginkgo Biloba for the Prevention of Cognitive Decline
Neurol 70:1807-1817,1730, Dodge,H.H.,et al, 2008
Statin Use and the Risk of Incident Dementia
Arch Neurol 62:1047-1051, Rea,T.D.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
Arch Neurol 61:82-88, Zandi,P.P.,et al, 2004
Statins and the Risk of Dementia
Lancet 356:1627-1631, Jick,H.,et al, 2000
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
Antioxidants and Dementia
Lancet 349:1189-1190, Lethem,R.&Orrell,M., 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997